23.01.2021 08:51:35
|
FDA Approves Aurinia Pharma's Lupkynis - Second Lupus Nephritis Drug In A Month
(RTTNews) - The FDA has approved Aurinia Pharmaceuticals Inc.'s (AUPH) LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis.
LUPKYNIS, generically known as voclosporin, becomes the second FDA-approved therapy for lupus nephritis, with the first being GlaxoSmithKline plc's (GSK) BENLYSTA, which was approved as recently as last month.
Aurinia's LUPKYNIS is administered orally while BENLYSTA is administered intravenously (IV) or subcutaneously.
The global peak sales of LUPKYNIS are estimated to be in excess of $1 billion, according to the company.
Lupus nephritis is an inflammation of the kidney caused by Systemic Lupus Erythematosus - resulting in irreversible kidney damage and increasing the risk of kidney failure, cardiac events, and death. It is estimated that lupus nephritis affects about 200,000 people in the U.S.
AUPH closed Friday's trading at $14.86, down 2.17%.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Aurinia Pharmaceuticals Incmehr Nachrichten
06.11.24 |
Ausblick: Aurinia Pharmaceuticals vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
31.07.24 |
Ausblick: Aurinia Pharmaceuticals gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) |
Analysen zu Aurinia Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
Aurinia Pharmaceuticals Inc | 7,81 | -1,39% |